You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
SBC: LEUKOGENE THERAPEUTICS INC Topic: 102Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Novel SCD1 inhibitors for treatment of cancer
SBC: MODULATION THERAPEUTICS, INC. Topic: 102Project Summary Metabolic reprogramming plays a critical role in carcinogenesisin part due its ability to promote immune suppressive properties within tumorsHoweverit is unclear whether inhibition of fatty acid metabolism in tumors affects their immunogenicityHerewe show for the first time that inhibition of stearoyl CoA desaturaseSCDthe rate limiting enzyme involved in fatty acid synthesis conver ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Proteolytic Imaging of Remodeling Myocardium
SBC: Micro Vide, LLC Topic: NHLBIDESCRIPTIONprovided by applicantProteolytic Imaging of Remodeling Myocardium Abstract Heart attacksi emyocardial infarction or MIoccur in more thanmillion patients annuallyAdvances in interventional and pharmacological therapies have dramatically improved survival following the initial MIand patients are often surviving acute MI with more extensive myocardial injuryConsequentlythe number of patien ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Newborn Infant Vision Test
SBC: Precision Vision, Inc. Topic: NProject Summary! This STTR Phase II project continues the development of the Newborn Acuity Cardstm and the Newborn Contrast Cardstm Together these Newborn Cards form a new clinical test of visual acuity and contrast sensi tivity for use on newborn full term and preterm infants The stimuli are square wave gratings which the examiner presents to the infant in a fixation and following protocol ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of an Autism Spectrum Disorder Screening Test based upon Metabolic Profiling of Fresh Blood Samples
SBC: CIRCA BIOSCIENCE LLC Topic: 102Autism spectrum disorderASDis a neurodevelopmental disorder characterized by significant deficits in reciprocal social interactionsimpaired communication and restrictedrepetitive behaviorswith a prevalence ofinchildren in the USEarly intervention programs have been shown to be effective for improving IQlanguageand social skills for toddlers as young asmonths of ageDiagnosis of ASD is currently bas ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Continuous Monitoring of COVID-19 Symptomatology for Elderly Patients in Long Term Care Facilities Using Advanced, Soft, and Flexible Sensors Mounted on the Suprasternal Notch
SBC: Sonica LLC Topic: NIAPROJECT SUMMARY: COVID-19 is significantly more lethal in the elderly1 with the greatest risk in those cared for in long-term care facilities (LTCs) where mortality rates range from 19% to 72% worldwide. Monitoring COVID-19 infections in LTCs remains a particular challenging. The existing and a continued expected shortage of sufficient molecular COVID-19 testing coupled to false negative rates as ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Aminomethyl benzamides as novel anti Ebola agents
SBC: Chicago Biosolutions, Inc. Topic: NIAIDEbola EBOV and Marburg MARV viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral infection and pathogenes ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Nucleobase aminosugars with reduced ototoxicity
SBC: NUBAD LLC Topic: YPROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Screening the Ribosome for New Target Sites
SBC: NUBAD LLC Topic: NIAIDDESCRIPTION provided by applicant Nucleic acids are avenues for drug design both as therapeutics and as targets Here we propose to establish new methods for identifying antibiotic ribosome targets and lead compounds Targeting specific RNA such as rRNA which are involved in proliferation and survival of bacteria is a promising approach We are developing fast and low cost methods to screen s ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Aminoglycosides with reduced ototoxicity
SBC: NUBAD LLC Topic: NIAIDPROJECT SUMMARY Aminoglycosides are one of the cheapest and well known antibiotics in clinical use for over years but one of the major limitations in their use is their ototoxicity We are developing fast and low cost methods to develop aminoglycosides with anti ribosomal activities and reduced toxicity In this project we will identify novel aminoglycoside antibacterials that show reduced ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health